Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), and Kate McQueston, a program coordinator at CGD, write in the center’s “Global Health Policy” blog that a reduction in AIDS funding to Ethiopia from PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria “might be warranted due to epidemiological trends and improved efficiency, or might cripple progress as health programs dependent on external donors are cut back,” but “with the current poor status of basic information on beneficiaries and costs, it’s difficult to judge whether these cuts are good or bad.” They outline the history of AIDS funding in Ethiopia, posit what future funding might encompass, and say additional information is needed from PEPFAR, the Global Fund, and the Ethiopian government in order to know the true impacts of reduced funding (9/11).
In this episode of the Center for Global Development’s (CGD) “Global Prosperity Wonkcast,” CGD’s Lawrence MacDonald interviews Amanda Glassman, a senior fellow and director of the global health policy program at the center, about global health funding in “this austere budget climate.” In an accompanying blog post, MacDonald notes “generating ‘value for money’ (VFM) is a top concern for global health funding agencies and their donors, who want the biggest bang for their buck in terms of lives saved and diseases controlled.” According to the blog, the discussion focuses on the Global Fund to Fight AIDS, Tuberculosis and Malaria, “a multilateral agency that emerged from the G8 meeting process in 2002 when times were better and global health was seen as an area where money could make a difference” (9/5).
The Affordable Medicines Facility-malaria (AMFm) — an innovative financing mechanism that subsidizes the cost of artemisinin-based combination therapies (ACTs) in order to expand access to the most effective treatment for malaria — “brought more than 100 million doses of malaria drugs to clinics and pharmacies in 2011” and “also increased access to the top malaria medicines by 26 to 52 percent in six countries,” according to results from the first phase of the program, which is hosted and managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria, NPR’s “Shots” blog reports. The results of the evaluation, released on Wednesday in Washington, D.C., do not estimate how many lives were saved because of improved access to effective malaria medications, as “AMFm ran for only a year and half in most countries,” according to the blog. “The AMFm negotiated with drugmakers to reduce ACTs prices, and then the Global Fund subsidized the initial purchasing of the drugs by clinics and pharmacies,” the blog notes.
The Global Fund to Fight AIDS, Tuberculosis and Malaria has published Issue 8 of its newsletter, the “Global Fund News Flash.” The issue reports on the Board’s approval of a new funding approach; says “the Board extended the mandate of the Global Fund to host the Affordable Medicines Facility-malaria for another year after the end of its pilot phase in December”; notes the Global Fund adopted a code of conduct for grant recipients; and profiles Linda Mafu, head of civil society and political advocacy at the Global Fund (9/20).
Devex News Analysis Examines Democratic, Republican Party Platforms On Foreign Policy, Including Global Health
A Devex news analysis examines the Democratic and Republican platform positions on foreign policy following the party conventions, writing, “Even as pocketbook concerns continue to overshadow foreign policy issues on the campaign trail, in both Charlotte and Tampa, top-billed speakers made the case for the U.S. foreign aid program.” The article examines the core principles of each platform, notes that neither platform offers specifics on foreign aid spending, and discusses the platforms’ stances on certain foreign policy issues, including global health, food security, climate change, and gay rights.
“In mid-July, … the near-final draft of the independent evaluation of the Affordable Medicines Facility — Malaria (AMFm) was released,” Victoria Fan, a research fellow at the Center for Global Development (CGD), and Heather Lanthorn, a doctoral candidate at Harvard School of Public Health, write in this post in the center’s “Global Health Policy” blog. “Never intended to be an experiment or quasi-experiment, the pre-post evaluation of the AMFm has so far been interpreted cautiously and optimistically; we’re encouraged by this,” they write. “But given that the evaluation considers trends in the outcomes of interest before and after AMFm in only the chosen AMFm countries, the evaluation lacks a counterfactual or comparison group,” they continue and detail the findings of the report. They conclude, “Regardless of what is decided for the next phase of AMFm, we strongly recommend that resources be allocated for, at a minimum, tracking outcomes more frequently and also in the non-AMFm countries” (9/4).
Developing Countries NGO Delegation To Global Fund Submits Report Highlighting Challenges, Recommendations
The Center for Global Health Policy’s “Science Speaks” blog discusses a report by the developing countries NGO delegation to the Global Fund to Fight AIDS, Tuberculosis and Malaria, submitted recently to the Global Fund Secretariat. “Covering procedures involved in program planning, spending, accounting and in responding to realities on the ground, some of the issues it raises are likely to be addressed in the global charity’s new funding model, but some may not be, a delegation representative wrote in response to an inquiry from ‘Science Speaks,'” the blog notes and highlights some of the challenges and recommendations contained in the report (Barton, 9/4).
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria’s Transitional Funding Mechanism (TFM), stating, “Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM.” The news service notes, “Almost 25 percent of this combined total will go towards [tuberculosis (TB)], which represents a significant increase from the average 16 percent of funds allocated for TB since the Global Fund was created in 2002, according to a StopTB Partnership statement released in response” to the fund’s announcement. PlusNews notes, “Unlike regular grants, which can run for up to five years, those awarded under the TFM will be limited to two years, by which time the fund is expected to have launched its new funding model” (9/4).
The Coca-Cola Company and the Global Fund to Fight AIDS, Tuberculosis and Malaria have announced the expansion of a pilot project, called “Project Last Mile,” that uses Coca Cola’s “‘expansive global distribution system and core business expertise’ to help deliver critical medicines to remote parts of the world, beginning in rural Africa,” Pharma Times reports. “The public-private partnership was established in 2010 to help Tanzania’s government-run medicine distribution network, Medical Stores Department, build a more efficient supply chain by using Coca-Cola’s” delivery system model, the news service writes, adding, “The latest phase of the partnership, developed in cooperation with the likes of the Bill & Melinda Gates Foundation, Accenture and Yale University, will increase the availability of critical medicines to 75 percent of Tanzania and expand the initiative to Ghana and Mozambique” (Grogan, 9/26).
“The Global Fund to Fight AIDS, Tuberculosis and Malaria has released initial details on its new funding model, … [b]ut as the fund works to finalize the model before next year, civil society is criticizing the process for being untransparent and rushed,” IRIN reports in an article examining the draft model and reaction to it. Some groups have expressed concern over the fund’s decision to “base funding allocations for each diseases on previously used levels for up to one year,” while “many African civil society organizations have expressed dissatisfaction with the speed and transparency of the process,” IRIN writes. “The Global Fund board is expected to make a final decision on the model at its November board meeting,” the news service notes (9/25).